[{"address1": "Wallstra\u00dfe 16", "city": "Berlin", "zip": "10179", "country": "Germany", "phone": "49 89 2153 9035", "website": "https://atai.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.", "fullTimeEmployees": 54, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christian  Angermayer", "age": 46, "title": "Co-Founder & Chairman of the Supervisory Board", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 73104, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Srinivas G. Rao M.D., Ph.D.", "age": 55, "title": "Co-Founder, CEO & Executive Director", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 834460, "exercisedValue": 0, "unexercisedValue": 39375}, {"maxAge": 1, "name": "Ms. Anne  Johnson", "age": 55, "title": "Chief Financial Officer", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 574815, "exercisedValue": 0, "unexercisedValue": 32812}, {"maxAge": 1, "name": "Dr. Gerd G. Kochendoerfer Ph.D.", "age": 56, "title": "Chief Operating Officer", "yearBorn": 1968, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Glenn  Short Ph.D.", "age": 54, "title": "Chief Scientific Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Barrett J.D.", "age": 43, "title": "General Counsel & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevin  Craig M.D.", "age": 51, "title": "Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.01, "open": 3.93, "dayLow": 3.6, "dayHigh": 3.9521, "regularMarketPreviousClose": 4.01, "regularMarketOpen": 3.93, "regularMarketDayLow": 3.6, "regularMarketDayHigh": 3.9521, "payoutRatio": 0.0, "forwardPE": -5.7058825, "volume": 6673564, "regularMarketVolume": 6673564, "averageVolume": 5531325, "averageVolume10days": 5265350, "averageDailyVolume10Day": 5265350, "bid": 3.86, "ask": 3.9, "bidSize": 31, "askSize": 16, "marketCap": 823118720, "fiftyTwoWeekLow": 1.03, "fiftyTwoWeekHigh": 4.4, "priceToSalesTrailing12Months": 356.48276, "fiftyDayAverage": 3.0284, "twoHundredDayAverage": 1.9428, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 676127168, "profitMargins": 0.0, "floatShares": 113814313, "sharesOutstanding": 212144000, "sharesShort": 15839782, "sharesShortPriorMonth": 10185689, "sharesShortPreviousMonthDate": 1751241600, "dateShortInterest": 1753920000, "sharesPercentSharesOut": 0.0747, "heldPercentInsiders": 0.07779, "heldPercentInstitutions": 0.34778, "shortRatio": 1.81, "shortPercentOfFloat": 0.0959, "impliedSharesOutstanding": 212144000, "bookValue": 0.731, "priceToBook": 5.3077974, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -119404000, "trailingEps": -0.69, "forwardEps": -0.68, "enterpriseToRevenue": 292.822, "enterpriseToEbitda": -7.128, "52WeekChange": 1.961832, "SandP52WeekChange": 0.15005577, "quoteType": "EQUITY", "currentPrice": 3.88, "targetHighPrice": 16.0, "targetLowPrice": 7.0, "targetMeanPrice": 11.28571, "targetMedianPrice": 11.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 95943000, "totalCashPerShare": 0.488, "ebitda": -94860000, "totalDebt": 9216000, "quickRatio": 3.756, "currentRatio": 4.019, "totalRevenue": 2309000, "debtToEquity": 6.403, "revenuePerShare": 0.013, "returnOnAssets": -0.29507, "returnOnEquity": -0.76499003, "grossProfits": 2309000, "revenueGrowth": 1.634, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -35.15021, "financialCurrency": "USD", "symbol": "ATAI", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Atai Life Sciences N.V.", "regularMarketChangePercent": -3.2419, "regularMarketPrice": 3.88, "shortName": "ATAI Life Sciences N.V.", "marketState": "CLOSED", "exchange": "NGM", "messageBoardId": "finmb_710359021", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "postMarketTime": 1755301907, "regularMarketTime": 1755288001, "cryptoTradeable": false, "corporateActions": [], "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1624023000000, "postMarketChangePercent": 0.0, "postMarketPrice": 3.88, "postMarketChange": 0.0, "regularMarketChange": -0.13, "regularMarketDayRange": "3.6 - 3.9521", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 5531325, "fiftyTwoWeekLowChange": 2.8500001, "fiftyTwoWeekLowChangePercent": 2.7669904, "fiftyTwoWeekRange": "1.03 - 4.4", "fiftyTwoWeekHighChange": -0.52, "fiftyTwoWeekHighChangePercent": -0.11818181, "fiftyTwoWeekChangePercent": 196.1832, "earningsTimestamp": 1755057600, "earningsTimestampStart": 1763037000, "earningsTimestampEnd": 1763037000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.69, "epsForward": -0.68, "epsCurrentYear": -0.50667, "priceEpsCurrentYear": -7.6578445, "fiftyDayAverageChange": 0.85160017, "fiftyDayAverageChangePercent": 0.28120467, "twoHundredDayAverageChange": 1.9372001, "twoHundredDayAverageChangePercent": 0.9971176, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-18", "averageAnalystRating": "1.2 - Strong Buy", "displayName": "Atai Life Sciences", "trailingPegRatio": null, "__fetch_time": "2025-08-16"}]